DS-8201a

Known as: ADC DS-8201a, Anti-HER2 ADC DS-8201a, Anti-HER2-DX-8951 Derivative ADC DS-8201a 
An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
02420062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Anti-HER2 therapies are beneficial for patients with HER2-positive breast or gastric cancer. T-DM1 is a HER2-targeting antibody… (More)
Is this relevant?
2016
2016
PURPOSE An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2016
2016
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BACKGROUND Despite multiple new therapies available to patients with advanced castration-resistant prostate cancer (CRPC), the… (More)
Is this relevant?
2015
2015
BACKGROUND Antibody-drug conjugates (ADCs) are an emerging class of cancer therapies that have demonstrated favorable activity… (More)
Is this relevant?
2015
2015
BACKGROUND It is timely and important to develop new treatment modalities for advanced prostate cancer, because even the newly… (More)
Is this relevant?
2013
2013
119 Background: The abundant expression of prostate specific membrane antigen (PSMA) on prostate cancer cells provides a… (More)
Is this relevant?
2011
2011
Prostate-specific membrane antigen (PSMA) is a membrane protein that is overexpressed manifold in prostate cancer and provides an… (More)
  • table 1
Is this relevant?
2011
2011
158 Background: The unique expression of PSMA type II transmembrane glycoprotein on prostate cancer cells provides a potentially… (More)
Is this relevant?
2009
2009
PURPOSE Intergroupe Francophone de Cancérologie Thoracique-0401 phase II trial aimed to evaluate the efficacy and safety of… (More)
Is this relevant?